Physician profile
Andrew B Dold
NPI 1073718516
$1,147,203.91
in general payments reported to CMS, 2019-2025
35 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116K · 2020: $56K · 2021: $99K · 2022: $147K · 2023: $293K · 2024: $231K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400K · Travel and Lodging: $251K · Consulting Fee: $45K · Food and Beverage: $33K · Education: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $399,878.88 |
| Travel and Lodging | $250,803.97 |
| Consulting Fee | $44,681.94 |
| Food and Beverage | $32,894.81 |
| Education | $1,298.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $606,902.54 | 2019-2025 | Nuzyra |
| Insmed, INC. | $162,680.56 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $124,481.47 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Melinta Therapeutics, LLC | $85,549.49 | 2019-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Gilead Sciences, INC. | $42,583.21 | 2019-2025 | Biktarvy, Sunlenca |
| Merck Sharp & Dohme LLC | $25,865.73 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Ferring Pharmaceuticals INC. | $20,430.26 | 2023-2025 | Rebyota |
| Astellas Pharma US INC | $18,618.06 | 2019-2025 | Cresemba |
| Allergan, INC. | $18,097.82 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $10,739.35 | 2022-2025 | Vibativ |
| Tetraphase Pharmaceuticals, INC. | $9,722.85 | 2019-2025 | |
| Shionogi INC | $9,615.81 | 2021-2025 | Fetroja |
| Pfizer INC. | $4,181.93 | 2021-2025 | |
| Cipla USA INC. | $1,172.82 | 2021 | |
| Janssen Biotech, INC. | $1,172.79 | 2019-2023 | Symtuza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,121.16 | 2020-2025 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $1,013.00 | 2022 | |
| Abbvie INC. | $616.18 | 2019-2025 | Dalvance, Teflaro |
| Theratechnologies INC. | $440.89 | 2019-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Grifols USA, LLC | $421.49 | 2019-2025 | Xembify, Gamunex-C |
| La Jolla Pharmaceutical Company | $391.22 | 2021-2025 | Xerava, Zevtera |
| Octapharma USA, INC. | $296.06 | 2020-2022 | |
| Janssen Products, Lp | $189.47 | 2019-2022 | |
| Csl Behring | $154.40 | 2022-2023 | Hizentra |
| Nabriva Therapeutics, Plc | $149.98 | 2020-2021 | |
| Emd Serono, INC. | $113.38 | 2019-2021 | |
| Adma Biomanufacturing LLC | $101.44 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $83.27 | 2023 | |
| Napo Pharmaceuticals INC | $72.93 | 2025 | Mytesi |
| Mayne Pharma Commercial LLC | $69.78 | 2020-2021 | |
| Angiodynamics, INC. | $46.25 | 2025 | Angiovac |
| Janssen Pharmaceuticals, INC | $39.22 | 2021-2023 | |
| Horizon Therapeutics Plc | $33.60 | 2019 | |
| Grt US Holding, INC. | $19.44 | 2021 | |
| Pharming Healthcare, INC. | $16.06 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.